Download PDF
Zentralbl Gynakol 2003; 125(9): 362-367
DOI: 10.1055/s-2003-43036
Originalarbeit

© Georg Thieme Verlag Stuttgart · New York

uPA und PAI-1 haben nicht nur eine prognostische, sondern auch eine prädiktive Bedeutung und unterstützen klinische Therapieentscheidungen beim primären Mammakarzinom

u-Plasminogen Activator (Urinary Plasminogen Activator, Urokinase) (uPA) and its PA-1 Type 1 Inhibitor are not only Prognostically but also Predictively Significant and Support Clinical Decisions on Therapy in Primary Carcinoma of the BreastN. Harbeck1 , C. Thomssen2
  • 1Frauenklinik der Technischen Universität München
  • 2Universitätsfrauenklinik Hamburg Eppendorf
Further Information

Publication History

Publication Date:
21 October 2003 (online)

    Permissions and Reprints

Zusammenfassung

uPA und PAI-1 sind die ersten neuen tumorbiologischen Prognosefaktoren beim Mammakarzinom, deren prognostische Bedeutung auf höchstem Evidenzniveau nachgewiesen wurde, und für die somit alle Evaluierungskriterien vor Überführung in die Klinik erfüllt sind. Patientinnen mit einem hohen Gehalt an uPA und/oder PAI-1 im Primärtumorgewebe haben eine signifikant geringere Heilungswahrscheinlichkeit als Patientinnen mit niedrigem uPA und PAI-1. Im Rahmen der mit dem Schmidt-Matthiesen-Preis 2002 ausgezeichneten Arbeit konnten wir erstmals zeigen, dass uPA und PAI-1 über ihre prognostische Bedeutung hinaus auch eine prädiktive Bedeutung hinsichtlich des Ansprechens auf adjuvante Chemotherapie besitzen. Patientinnen mit hohem uPA/PAI-1 haben einen signifikant größeren Nutzen von adjuvanter Chemotherapie als Patientinnen mit niedrigem uPA/PAI-1. Das Ansprechen auf adjuvante endokrine Therapie ist unabhängig vom uPA/PAI-1-Status. Die resultierende Frage nach der optimalen Chemotherapie für Patientinnen mit hohem uPA/PAI-1 versuchen derzeit in Deutschland die NNBC-3-Studie beim nodal-negativen Mammakarzinom (AGO, EORTC-RBG) sowie die ADEBAR-Studie bei Patientinnen mit ≥ 4 befallenen axillären Lymphknoten zu beantworten. Gleichzeitig legen diese Ergebnisse den frühzeitigen Einsatz neuer mit dem uPA-System interferierender tumorbiologischer Therapeutika in Kombination mit konventioneller Chemotherapie bei Patientinnen mit hohem uPA/PAI-1 nahe.

Abstract

uPA and PAI-1 are the first novel tumor biological prognostic factors in breast cancer for which the prognostic impact has been validated at the highest level of evidence and hence all evaluation criteria for transfer into clinical practice have been fullfilled. Breast cancer patients with high uPA and/or PAI-1 levels in their primary tumor tissue have a significantly lower chance for cure than patients with low levels of both uPA and PAI-1. Our research that was honored with the Schmidt-Matthiesen-Award 2002 shows for the first time that uPA and PAI-1 are not only prognostic factors but also have a predictive impact with regard to response to adjuvant chemotherapy. Patients with high uPA/PAI-1 derive a significantly greater benefit from adjuvant chemotherapy than patients with low uPA/PAI-1. Benefit from adjuvant endocrine therapy is independent of uPA/PAI-1 status. The resulting question about the optimal chemotherapy for patients with high uPA/PAI-1 is currently being addressed in Germany by the NNBC-3 trial in node-negative breast cancer (AGO, EORTC-RBG) as well as the ADEBAR trial in patients with 4 or more involved axillary lymph nodes. Moreover, our results suggest the use of novel therapeutic agents interfering with the uPA system together with conventional chemotherapy in patients with high uPA/PAI-1 already in early stage disease.

Schlüsselwörter

uPA - Mammakarzinom - NNBC-3 - nodal-negativ - PAI-1 - Prognose - Prädiktion von Therapieansprechen

Key words

uPA - PAI-1 - breast cancer - NNBC-3 - node-negative - prognosis - prediction of therapy response

Literatur

  • 1 Andreasen P A, Kjöller L, Christensen L, Duffy M J. The urokinase-type plasminogen activator system in cancer metastasis: A review.  Int J Cancer. 1997;  72 1-22
    CrossrefPubMedGoogle Scholar
  • 2 Bouchet C, Spyratos F, Martin P M, HacPne K, Gentile A, Oglobine J. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.  Br J Cancer. 1994;  69 398-405
    PubMedGoogle Scholar
  • 3 Duffy M J, O 'Grady P, Devaney D, O'Sioran L, Fennelly J J, Lijnen H. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas.  Cancer. 1988;  62 531-533
    PubMedGoogle Scholar
  • 4 Eppenberger U, Kueng W, Schlaeppi J M, Roesel J L, Benz C, Mueller H, Matter A, Zuber M, Luescher K, Litschgi M, Schmitt M, Foekens J, Eppenberger-Castori S. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients.  J Clin Oncol. 1998;  16 3129-3136
    PubMedGoogle Scholar
  • 5 Fernö M, Bendahl P O, Borg Å, Brudell J, Hirschberg L, Olsson H, Killander D. Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay.  Eur J Cancer. 1996;  32 A 793-801
    CrossrefPubMedGoogle Scholar
  • 6 Foekens J A, Schmitt M, van Putten W LJ, Peters H A, Kramer M D, Jänicke F, Klijn J GM. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.  J Clin Oncology. 1994;  12 1648-1658
    PubMedGoogle Scholar
  • 7 Foekens J A, Look M P, Peters H A, van Putten W LJ, Portengen H, Klijn J GM. Urokinase-type plasminogen activator and its inhibitor PAI-1: Predictors of poor response to tamoxifen therapy in recurrent breast cancer.  J Natl Cancer Inst. 1995;  87 751-756
    CrossrefPubMedGoogle Scholar
  • 8 Grøndahl-Hansen J, Peters H A, van Putten W LJ, Look M P, Pappot H, Rønne E, Danø K, Klijn J GM, Brünner N, Foekens J A. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer.  Clin Cancer Res. 1995;  1 1079-1087
    PubMedGoogle Scholar
  • 9 Goldhirsch A, Glick J H, Gelber R D, Coates A S, Senn H J. Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer.  J Clin Oncol. 2001;  19 (18) 3817-3827
    PubMedGoogle Scholar
  • 10 Harbeck N, Dettmar P, Thomssen C, Berger U, Ulm K, Kates R, Jänicke F, Höfler H, Graeff H, Schmitt M. Risk-group discrimination in node- negative breast cancer using invasion and proliferation markers: six-year median follow- up.  Br J Cancer. 1999;  80 419-426
    CrossrefPubMedGoogle Scholar
  • 11 Harbeck N, Look M P, Ulm K, Duffy M J. on behalf of the Pooled Analysis Study of the EORTC Receptor and Biomarker Group (RBG) . uPA and PAI-1 ready for routine testing in primary breast cancer: pooled analysis (n = 8 377) provides level-1 evidence for clinical relevance.  ASCO Proceedings. 2001;  1646
    PubMedGoogle Scholar
  • 12 Harbeck N, Alt U, Krüger A, Berger U, Thomssen C, Jänicke F, Kates R, Schmitt M. Prognostic impact of proteolytic factors (uPA, PAI-1, cathepsins B, D, L) in primary breast cancer reflects effects of adjuvant systemic therapy.  Clin Cancer Res. 2001;  7 2757-2764
    PubMedGoogle Scholar
  • 13 Harbeck N, Meisner C, Prechtl A, Untch M, Selbmann H K, Sweep C GJ, Graeff H, Schmitt M, Jänicke F, Thomssen C. for the German Chemo-N0 Study Group . Level-I evidence for prognostic and predictive impact of uPA and PAI-1 in node-negative breast cancer provided by second scheduled analysis of multicenter Chemo-N0 therapy trial.  Breast Cancer Res Treat. 2001;  69 213
    PubMedGoogle Scholar
  • 14 Harbeck N, Kates R E, Look M P, Meijer-van Gelder M E, Klijn J GM, Jänicke F, Krüger A, Kiechle M, Schmitt M, Foekens J A. Enhanced benefit from adjuvant systemic chemotherapy in breast cancer patients classified high-risk according to uPA and PAI-1 (n = 3 424).  Cancer Res. 2002;  62 (16) 4617-4622
    PubMedGoogle Scholar
  • 15 Harbeck N, Kates R, Schmitt M. Clinical relevance of invasion factors uPA and PAI-1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.  J Clin Oncology. 2002;  20 1000-1009
    PubMedGoogle Scholar
  • 16 Hayes D F, Bast R C, Desch C E, Fritsche H, Kemeny N E, Jessup J M, Locker G Y, Macdonald J S, Mennel R G, Norton L, Ravdin P, Taube S, Winn R J. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers.  J Natl Cancer. 1996;  88 1456-1466
    CrossrefPubMedGoogle Scholar
  • 17 Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Höfler H, Graeff H. Urokinase (uPA) and its inhibitor (PAI-1) are strong and independent prognostic factors in node-negative breast cancer.  Breast Cancer Res. 1993;  24 195-208
    PubMedGoogle Scholar
  • 18 Jänicke F, Thomssen C, Pache L. et al .Urokinase (uPA) and PAI-1 as selection criteria for adjuvant chemotherapy in axillary node-negative breast cancer patients. In: Schmitt M, Graeff H, Jänicke F (eds). Prospects in diagnosis and treatment of cancer. Elsevier Science, Netherlands 1994; 207-218
    Google Scholar
  • 19 Jänicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, Sweep C G, Selbmann H K, Graeff H, Schmitt M. for the German Chemo N0 Study Group . Randomized adjuvant therapy trial in high-risk lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type I.  J Natl Cancer Inst. 2001;  93 913-920
    CrossrefPubMedGoogle Scholar
  • 20 Kim S J, Siba E, Kobayashi T, Yayoi E, Furukawy J, Takatsuka Y, Shin E, Koyama H, Inaji H, Takai S. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1 and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis.  Clin Cancer Res. 1998;  4 177-182
    PubMedGoogle Scholar
  • 21 Knoop A, Andreasen P A, Andersen J A, Hansen S, Lænkholm A V, Simonsen A CW, Andersen J, Overgaard J, Rose C. Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer.  Br J Cancer. 1998;  77 932-940
    CrossrefPubMedGoogle Scholar
  • 22 Konecny G, Untch M, Arboleda J, Wilson C, Kahlert S, Boettcher B, Felber M, Beryt M, Lude S, Hepp H, Slamon D, Pegram M. HER-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.  Clin Cancer Res. 2001;  7 2448-2457
    PubMedGoogle Scholar
  • 23 Kute T E, Grøhndahl-Hansen J, Shao S M, Long R, Russell G, Brü nner N. Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence.  Breast Cancer Res. 1998;  47 9-16
    PubMedGoogle Scholar
  • 24 Look M P, van Putten W LJ, Duffy M J, Harbeck N, Brünner N, Kates R, Fernö M, Eppenberger S, Spyratos F, Thomssen C, Sweep C GJ, Peyrat J P, Martin P M, Blankenstein M A, Magdelenat H, Quillien-Pouvreau V, Daver A, Ricolleau G, Daxenbichler G, Cufer T, Bendahl P O, Lisboa B, Ulm K, Christensen I J, Meijer-van Gelder M E, Fiets E, Manders P, Broët P, Romain S, Windbichler G, Borstnar S, Beex L VRM, Jänicke F, Klijn J GM, Eppenberger U, Schmitt M, Foekens J A. Pooled analysis of prognostic impact of uPA and PAI-1 in 8 377 breast cancer patients.  J Natl Cancer Inst. 2002;  94 116-128
    CrossrefPubMedGoogle Scholar
  • 25 Pierga J Y, Laine-Bidron C, Beuzeboc P, DeCremoux P, Pouillart P, Magdelenat H. Plasminogen activator inhibitor-1 (PAI-1) is not related to response to neoadjuvant chemotherapy in breast cancer.  Br J Cancer. 1997;  76 537-540
    PubMedGoogle Scholar
  • 26 Schmitt M, Wilhelm O G, Reuning U, Krüger A, Harbeck N, Lengyel E, Graeff H, Gä nsbacher B, Kessler H, Bürgle M, Stürzebecher J, Sperl S, Magdolen V. The plasminogen activaton system as a novel target for therapeutic strategies.  Fibrinolysis. 2000;  14 114-132
    PubMedGoogle Scholar
  • 27 Sweep C GJ, Geurts-Moespot J, Grebenschikov N, de Witte J H, Heuvel J JTM, Schmitt M, Duffy M J, Jänicke F, Kramer M D, Foekens J A, Brünner N, Brugal G, Pedersen A N, Benraad T J. External quality assessment of trans-european multicentre antigen determinations (ELISA) of urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-1) in human breast cancer tissue extracts.  Br J Cancer. 1998;  78 1434-1441
    PubMedGoogle Scholar
  • 28 Yamauchi H, Stearns V, Hayes D F. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer.  J Clin Oncol. 2001;  19 2334-2356
    PubMedGoogle Scholar
  • 29 Zemzoum I, Kates R E, Ross J S, Dettmar P, Dutta M, Henrichs C, Yurdseven S, Höfler H, Kiechle M, Schmitt M, Harbeck N. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.  J Clin Oncol. 2003;  21 1022-1028
    CrossrefPubMedGoogle Scholar

OÄ Priv.-Doz. Dr. med. Nadia Harbeck

Frauenklinik und Poliklinik, Klinikum rechts der Isar

Technische Universität München

Ismaninger Straße 22

81675 München

Phone: 0 89/41 40-24 19

Fax: 0 89/41 40-48 46

Email: nadia.harbeck@lrz.tum.de

      >